Key result
A pharmacist-led approach revealed that 86% of verified anticoagulation treatment gaps in atrial fibrillation patients were already explained and did not require further action.
Why the study?
Anticoagulation reduces stroke risk in atrial fibrillation, yet 40-50% of eligible patients are not prescribed anticoagulants, representing an apparent quality-of-care gap.
Does a pharmacist-led chart review and provider outreach approach accurately identify true anticoagulation treatment gaps in adult primary care patients with atrial fibrillation?
Does a pharmacist-led chart review and provider outreach approach accurately identify true anticoagulation treatment gaps in adult primary care patients with atrial fibrillation?
Claims and EHR-based algorithms may substantially overestimate gaps in anticoagulation care for atrial fibrillation, as most apparent gaps have valid clinical explanations identified by pharmacist review.
Answers are grounded in this paper and cite their sources.
Pharmacist-led gap closure may boost anticoagulation rates in primary care AF; leaves open effects on stroke, bleeding, and broad adoption.
INTRODUCTION: Risk of stroke is greater in patients with atrial fibrillation. Anticoagulation is effective at decreasing risk, yet 40-50% of eligible patients are not prescribed anticoagulation and seem to have a concerning gap in care quality. This quality improvement initiative implemented a pharmacist-led approach to identify, verify, and close apparent anticoagulation treatment gaps. METHODS: We included adult primary care patients with diagnosis of atrial fibrillation; congestive heart failure, hypertension, age ≥75 years (doubled), diabetes, stroke/transient ischemic attack (doubled), vascular disease, age 65-74 years, and sex (female) (CHA 2 DS 2 -VASc) score of at least 2, and no current anticoagulant use. We identified patients using claims and electronic health record data and evaluated explanations through chart review and provider contact. A provider outreach protocol was developed and implemented to address opportunities for anticoagulation. RESULTS: Of 242 patients with an apparent gap, 84% had a verified treatment gap. However, 86% of verified treatment gaps were explained through pharmacist chart review and outreach to providers, and they did not require further action. Explanations included spontaneous resolution of atrial fibrillation, patient declining treatment, completion of a procedure to correct atrial fibrillation or mitigate stroke risk, and high bleeding risk. CONCLUSIONS: Relying solely on claims- and electronic health record-based algorithms may substantially overestimate gaps in care quality.
No takes yet. Share an insight, caveat, or question.
Terry et al. (2024) studied Atrial Fibrillation (n=242). Pharmacist-led chart review and provider outreach was evaluated on Verified treatment gap. A pharmacist-led approach revealed that 86% of verified anticoagulation treatment gaps in atrial fibrillation patients were already explained and did not require further action.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: